.png)
research
White Papers, Case Studies, Reports
Tufts CSDD Impact report: Decentralized and hybrid trials deliver greater ROI than traditional trials
ROI
6 min
The Tufts Center for the Study of Drug Development completed an analysis of its financial modeling study of decentralized clinical trials using real data from Medable-enabled studies. These findings net financial benefits ranging from 5x for Phase II and 13x for Phase III trials, equating to roughly $10 million ROI and $39 million ROI, respectively.
Speakers
No items found.
Research
Assessing the financial value of decentralized clinical trials
Tufts CSDD
6 min
Deployment of remote and virtual clinical trial methods and technologies, referred to collectively as decentralized clinical trials (DCTs), represents a profound shift in clinical trial practice. To our knowledge, a comprehensive assessment of the financial net benefits of DCTs has not been conducted